Castellum, Inc.
AMEX:CTMInformation Technology Services
+$0.04 today
- Market cap
- $50.04M
- Beta
- -4.26
- P/E (TTM)
- -49.2
- EPS (TTM)
- -$0.02
Volume 0.23M
Average 3.94M
CTM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Castellum, Inc.AMEX: CTM
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How CTM compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 0.0% of revenue for CTM, versus a peer median of 8.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
RDZNRoadzen, Inc. | LTM Dec 2025 | $293.96B USD | +5386358.2% | +42.5% | 584354.8% |
| LTM Mar 2026 | $19.86M USD | — | — | 11.0% | |
| LTM Mar 2026 | $16.21M USD | +12.3% | +16.5% | 16.2% | |
| LTM Mar 2026 | $5.54M USD | -10.3% | +1.9% | 38.2% | |
| LTM Mar 2026 | $4.9M USD | +9.2% | +4.7% | 17.5% | |
| LTM Mar 2026 | $3.38M USD | +9.7% | +1.8% | 5.8% | |
| LTM Mar 2026 | $3M USD | -54.5% | -30.7% | 2.5% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Mar 2026 | -$129K USD | -106.6% | -77.7% | 2.6% | |
| Peer median (excluding CTM) | — | -0.5% | +1.9% | 8.4% | |
Competitors are the stored peer set for CTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 25.07M | 42.19M | 45.24M | 44.76M | 52.87M |
| Cost of Revenue | 13.99M | 24.59M | 26.57M | 26.5M | 33.5M |
| Gross Profit | 11.07M | 17.6M | 18.68M | 18.27M | 19.37M |
| Gross Margin | 44.2% | 41.7% | 41.3% | 40.8% | 36.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 14.54M | 13.59M | 17.7M | 14.33M | 10.7M |
| Operating Expenses | 18.8M | 27.56M | 35.34M | 25.51M | 22.18M |
| Depreciation & Amortization | 1.89M | 2.03M | 2.53M | 2.22M | 1.5M |
| EBITDA | (5.8M) | (8.06M) | (13.28M) | (6.53M) | (285.54K) |
| EBITDA Margin | -23.1% | -19.1% | -29.4% | -14.6% | -0.5% |
| Operating Income | (7.73M) | (9.96M) | (16.67M) | (7.24M) | (2.81M) |
| Operating Margin | -30.8% | -23.6% | -36.8% | -16.2% | -5.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.52M | 3.99M | 3.25M | 1.16M | 405.91K |
| Other Income / Expenses | (2.48M) | (4.12M) | (2.39M) | (2.67M) | 624.25K |
| Income Before Tax | (10.2M) | (14.09M) | (19.06M) | (9.91M) | (2.19M) |
| Pre-Tax Margin | -40.7% | -33.4% | -42.1% | -22.1% | -4.1% |
| Income Tax Expense | (2.66M) | 819.6K | (1.26M) | 68.03K | 207.98K |
| Net Income | (7.55M) | (14.91M) | (17.8M) | (9.98M) | (2.4M) |
| Net Margin | -30.1% | -35.3% | -39.3% | -22.3% | -4.5% |
| EPS (Basic) | (0.41) | (0.55) | (0.38) | (0.18) | (0.03) |
| EPS (Diluted) | (0.41) | (0.55) | (0.38) | (0.18) | (0.03) |
| Weighted Avg Shares | 18.23M | 27.47M | 47.18M | 55.29M | 94.7M |
| Weighted Avg Shares (Diluted) | 18.26M | 27.47M | 47.18M | 55.29M | 94.7M |
Castellum, Inc.
AMEX:CTM
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.